Major Pan-European report highlights stark inequalities in cancer treatment throughout Europe
A report by the Karolinska Institutet, in conjunction with the Stockholm School of Economics, exposes stark inequalities in patient access to cancer treatment across Europe and urges action by decision makers to redress these inequalities.
The report, entitled ‘A pan-European comparison regarding patient access to cancer drugs’, found that despite the proven benefits of new innovative treatments options, patients across Europe do not have equality of access to these cancer drugs and the speed at which patients can benefit from them depends to a great extent upon the country in which they live.
Nineteen countries, representing almost 75% of Europe’s population, were included in the report. Austria, Spain, and Switzerland are shown to be the leaders in terms of early adoption and availability of new cancer drugs whereas other countries, such as the UK, Czech Republic, Hungary Norway, and Poland lag behind.
“Patients have to wait too long to obtain the benefits of newer therapies and the biggest hurdle to the uptake of new drugs is the proactive allocation of financial resources and budget in the health care systems by policy and decision makers”, says Dr. Nils Wilking of the Karolinska Institutet.
Drs Wilking and Jönsson point out that the total healthcare cost for cancer in countries included in this report is an estimated 120 euros per citizen – only 5% of total healthcare expenditure. The cost of cancer drugs per capita ranges from 7 euros to 16 euros per citizen in Europe. Costs associated with inpatient hospital care costs dominate the direct costs of cancer in Europe, accounting for 60% to 94% of all costs and less than 10% is spent on drugs. The share of health care costs for cancer is much less than the share of burden of the disease.
“A superior approach for cancer patients in Europe would be to take a broader perspective on the benefits and costs these drugs bring to patients and society, and introduce a more rational system of allocation of resources to the healthcare system,” explained Dr. Bengt Jönsson of the Stockholm School of Economics. “It is worth emphasising that new treatments are usually targeted to specifically identifiable populations” ‘he continued. Dr Jönsson also added “There are examples of best practice in some countries which try to expedite patient access to innovative therapies - these should be assessed on their applicability for more countries in Europe.”
The report also argues that while new therapies generally increase health expenditure, the value they bring to patients in terms of survival and treating their cancer must be recognized. Research undertaken in the U.S. by Dr. Frank Lichtenberg of Columbia University suggests that access to more and newer cancer drugs improves survival rates.
For further information, please contact:
Nils Wilking, mobile +46 73 625 17 19, e-mail: email@example.com
Bengt Jönsson, mobile +46 70 847 03 63, e-mail Bengt.Jonsson@hhs.se
Sabina Bossi | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...